I started out as a cardiovascular primary care sales rep with Merck in the UK.
Julia Walker
Senior Director, Brand Corporate Affairs, AstraZeneca
I started out as a cardiovascular primary care sales rep with Merck in the UK. During that time, the results of the landmark 4S study [Scandinavian Simvastatin Survival Study] made major news on front pages and broadcast outlets around the world. That was my first real taste for what public relations could do and what it was all about. My agency experience really afforded me the best opportunity to get to know our key stakeholder: the media.
I'm most proud of the work I've done on our cholesterol-lowering, atherosclerosis-slowing statin, Crestor. Specifically, the work done by our brand corporate affairs team was a key reason AstraZeneca was able to shift its communications strategy from one of a defensive posture to a more proactive, results-oriented approach. Ultimately, transparent communication of the scientific data for Crestor helped prove the various allegations being made were indeed misleading and inaccurate. Now, thanks to a well-coordinated awareness and education effort, Crestor is helping millions of patients lower their cardiovascular risk, and is the only branded statin that continues to gain market share.
All leaders, at some point in their professional (and probably personal) lives, have operated under the philosophy of "if you want it done right, do it yourself." I'm certainly no exception to that rule. Avoidance of micromanaging is the hardest part of the transition from being a doer to being a manager. The team I've helped build and the agency partners in which I've put my trust have made it easier for me to let go. Still, that doesn't just happen at the drop of a hat. It takes a great deal of work to nurture and mentor a team to be ready to take on roles and responsibilities that you would otherwise handle yourself.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.